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PKCAntigen binding to B cell receptor (BCR) of pre-mature B lymphocytes leads to their apoptosis, while binding
to BCR of mature B lymphocytes induces their activation and proliferation. The former binding is believed to
be a mechanism so as to exclude B cell clones leading to protection from auto-immune diseases. Cross-
linking of BCR of pre-mature B cells, including chicken DT40 cells, with anti-immunoglobulin antibody
induces their apoptosis. The PMA/ionomycin treatments, which mimic BCR stimulation, are used to study
intracellular signal transduction of B lymphocytes. Here, by analyzing the Aiolos-deﬁcient DT40 cell line,
Aiolos−/−, we reveal that the lack of Aiolos accelerates apoptosis of DT40 cells mediated by BCR signaling.
Moreover, the Aiolos-deﬁciency and BCR signaling cooperatively control this apoptosis through dramatically
elevated cytochrome c release from mitochondria to cytosol and elevated caspase (caspase-3, 8 and 9)
activities, resulting in drastically diminished amounts of ICAD followed by increased DNA fragmentation. Re-
expression study reveals that the shorter isoform of Aiolos (Aio-2) controls PMA/ionomycin-mediated
apoptosis via up-regulation and down-regulation of the PKCδ and bak genes, respectively. These ﬁndings
could be a powerful trigger to resolve molecular mechanisms of negative selection of B lymphocytes and also
auto-immune diseases.© 2009 Elsevier B.V. All rights reserved.1. Introduction
The normal development of B lymphocytes requires numerous
transcription factors, including Ikaros [1], Aiolos [2], E2A [3], EBF [4],
Pax5 [5], PU.1 [6], and so on [7,8]. Deletions of some of these factors
result in the developmental stop and/or abnormality at early stage of
the B cell differentiation from hematopoietic stem cells, suggesting
that each of them plays a critical role in the B cell development. Aiolos,
a member of Ikaros family [9], is ﬁrst detected in committed
precursors, dramatically enhanced at the pre-B (and pre-T) cell
stage of the development, and detected in mature lymphocytes. Its
highest expression is observed in mature peripheral B cells [9–14]. In
the periphery of Aiolos-deﬁcient mice, B cells exhibit an activated cell
surface phenotype [2] and the B cells of Aiolos lacking mice possess anehydephosphate dehydrogen-
ium iodide; PMA, phorbol 12-
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ll rights reserved.enhanced B cell receptor (BCR) signaling response [2,15]. Aiolos-
deﬁcient mice also develop a systemic lupus erythematosus (SLE)
type autoimmune disease [16]. As mentioned above, noticeably, the
Aiolos gene is widely expressing through the normal developmental
stage from pro-B cells to mature B cells [7,8]. Recently, Thompson et al.
showed that pre-BCR signaling regulates Aiolos expression via the
adaptor protein SLP-65 [17]. In addition, it has been reported that
Aiolos is up-regulated in chronic lymphocytic leukemia [18]. However,
its physiological functions remain poorly deﬁned, particularly in each
developmental stage of B lymphocytes.
On the other hand, strengthened BCR signaling exhibits important
impacts in the early B cell ontogeny, survival of pre-mature B cells, and
fate decision and maintenance of mature B cells [19–24]. B
lymphocytes are susceptible to receptor- and/or mitochondria-
initiated cell death at various stages of peripheral differentiation and
during immune responses [20,25], and aberrant BCR signals mediate
apoptosis following recognition of self-antigens [20]. Genetic evi-
dences have greatly contributed to understanding of the BCR-
dependent survival mechanisms of mature B cells [26–29]. Although
Aiolos has been known to interact with anti-apoptotic factor bcl-xL
[30] and to regulate bcl-2 gene expression [31] in T cells, regulation
mechanisms of the BCRmediated apoptosis by it (and also other B cell
speciﬁc factors) still remain unclear in pre-mature B cells.
1305H. Kikuchi et al. / Biochimica et Biophysica Acta 1793 (2009) 1304–1314Recently, using gene targeting techniques in the DT40 cell line
derived from chicken pre-mature B cells, we clariﬁed that HDAC2 up-
regulates gene expressions of EBF1, Pax5, Aiolos, Ikaros plus HDAC7, and
down-regulates thoseof E2A, PCAF, HDAC4plusHDAC5 [32]. Further,we
revealed that EBF1 and Aiolos down-regulate expressions of IgM H and
L-chain genes, while E2A up-regulates expressions of them [32]. These
results, together with our previous results [33,34] and others [35],
indicate that HDAC2 indirectly controls the expression of IgM H and L-
chain genes, through up-regulated transcriptional regulation of EBF1,
Pax5, Aiolos and Ikaros, and down-regulated transcriptional regulation
of E2A. Moreover, it has also been reported that Aiolos controls gene
conversion and cell death in DT40 cells using gene targeting techniques
[36], but molecular mechanism of the acceleration of apoptosis in the
Aiolos-deﬁcient DT40 mutant, Aiolos−/− remains to be resolved. Here,
based on these results, by analyzing Aiolos−/− generated by us [32], we
clariﬁed the participatory molecular mechanism of Aiolos in the pre-
mature B cell apoptosis mediated by BCR stimulation.
2. Materials and methods
2.1. Materials
Phorbol 12-myristate 13-acetate (PMA) (CALBIOCHEM), ionomy-
cin and puromycin (Sigma) were obtained. Anti-ICAD antibody, anti-
Bcl-2 antibody (SANTA CRUZ Biotechnology, Inc.), anti-caspase-3
antibody (QED Bioscience, Inc.), anti-β-actin antibody (Abcam, plc.),
horse radish peroxidase-conjugated goat anti-rabbit immunoglobulin,
horse radish peroxidase-conjugated rabbit anti-mouse immunoglo-
bulin (DAKO, Inc.) were used.
2.2. Cell cultures and apoptosis induction
Generation of Aiolos−/−was described in our previous report [32].
DT40 and its subclones were cultured essentially as described [37].
Apoptosis was induced as follows. Cells (2×106) in 10 ml of culture
medium were incubated with 10 ng/ml PMA plus 1 μM ionomycin or
10 μg/ml etoposide at 37 °C. Treatmentswith inhibitors for cPKCs (1 μM
Go6976) or nPKCs (1 μM Rottlerin) were carried out as follows. Cells
(2×106) in 10ml of culturemediumwere treatedwith each reagent at
37 °C for 1 h, and incubatedwith 10 ng/ml PMA and 1 μM ionomycin at
37 °C for 12 h. Viable cells were counted by the trypan blue dye
exclusion method. Flow cytometric analyses and morphological
analyses, respectively, were carried out using a FACSCalibur (BD
Biosciences) and a MX4000 (Meiji Techno) as described [37,38]. DNA
fragmentation assay was carried out as described [39].
2.3. Semiquantitative reverse transcription-polymerase chain reaction
(RT-PCR)
Total RNAs were isolated from DT40 and its subclones. RT was
performed with a ﬁrst strand DNA synthesis kit (TOYOBO) at 42 °C for
20 min, followed by heating at 99 °C for 5 min. PCRs were carried out
as described [37], using sense and antisense primers, which were
synthesized according to the EST data deposited in GenBank for
appropriate genes and listed in previous reports [32,37,38]. Chicken
glyceraldehydephosphate dehydrogenase (GAPDH) gene was used as
internal control. PCR products were subjected to 1.5% agarose gel
electrophoresis and analyzed using a luminescent image analyzer
LAS-1000plus (FUJIFILM). The nucleotide sequences of all ampliﬁed
RT-PCR products obtained were conﬁrmed by the PCR sequencing
method as described [37].
2.4. Immunoblotting
Cells were treated with 10% trichroloacetic acid (TCA), collected by
centrifugation, dissolved in 0.5 M Tris–HCl (pH 6.8) containing 2.5%sodium dodecyl sulfate (SDS), 10% glycerol, and 5% 2-mercaptoetha-
nol, and heated at 100 °C for 5 min. The samples were subjected to
SDS-polyacrylamide gel electrophoresis (PAGE) and electrotrans-
ferred onto polyvinyliden diﬂuoride (PVDF) membranes. The pro-
tein-transferred PVDF membranes were immersed in a 5% skim milk
solution in Tris-buffered saline and incubatedwith anti-ICAD antibody
at 4 °C overnight. Antibody binding was detected by using second
antibodies conjugated with horse radish peroxidase and SuperSignal
west Pico Chemiluminescent Substrate (PIERCE) as a substrate. Data
analyses were carried out using a luminescent image analyzer LAS-
1000plus (FUJIFILM). β-actin was used as a control.
2.5. Caspase activity assay
Caspase activities were assayed using Caspase-3/CPP32 Colori-
metric Assay Kit (for caspase-3, BioVision), FLICE/Caspase-8 Colori-
metric Assay Kit (for caspase-8, BioVision), and Caspase-9
Colorimetric Assay Kit (for caspase-9, BioVision). Absorbance at
405 nm was measured to determine caspase activities.
2.6. Cytochrome c releasing assay
Cytochrome c releasing assay was performed using Cytochrome c
Releasing Apoptosis Kit (BioVison) as follows. Cells (5×107) were
incubated with or without 10 ng/ml PMA and 1 μM ionomycin at 37 °C
for 4 h, collected by centrifugation at 4 °C, resuspended with Cytosol
Extraction Buffer and homogenized with a Dounce tissue grinder on
ice. The homogenates were transferred into tubes, centrifuged at 4 °C,
the supernatants were collected into fresh tubes and centrifuged at
4 °C. The supernatants and pellets obtained were used as cytosol and
mitochondria fractions, respectively. Cytochrome c was detected by
immunoblotting using anti-horse cytochrome c antibody (Santa Cruz
Biotechnology, Inc.) as a primary antibody. Bcl-2 was used as a control
to demonstrate purity of mitochondria and cytosolic fractions.
2.7. Re-expression study
To obtain the FLAG-tagged Aiolos expression vectors, two chicken
Aiolos cDNA fragments which encode the full-length isoform Aio-1
and the shorter isoform Aio-2 lacking exon 3 [11,36] respectively, were
generated by PCR ampliﬁcation using PrimeSTAR HS DNA polymerase
(Takara) and inserted into pApuro carrying the chicken β-actin
promoter upstream of the cloning site and a marker gene (the puro-
resistant gene) under the control of the SV40 promoter [40]. The
Aiolos−/− cells were transfected with the vectors using electropora-
tion and the clones were selected by puromycin (0.4 μg/ml).
3. Results
3.1. Moderate inﬂuences of Aiolos-deﬁciency on gene expressions of
apoptosis-related factors
To know inﬂuences of the Aiolos-deﬁciency on gene expressions of
apoptosis- and BCR signaling-related factors, and others, we carried
out semiquantitative RT-PCR on total RNAs prepared from DT40 and
Aiolos−/− (Fig. 1). In this study, we analyzed three independent
Aiolos−/− clones. The deﬁciency showed insigniﬁcant inﬂuences on
transcriptions of most of these genes, except for those of bak (to
∼200%), caspase-9 (to ∼180%) and ICAD (to ∼60%), and PKCα (to
∼50%), PKCβ (to ∼60%), PKCδ (to ∼10%), PKCɛ (to ∼35%), PKCη (to
∼25%), and PKCζ (to ∼25%), respectively. Moreover, transcriptions of
various genes encoding membrane-proximal factors, NF-κBs, tran-
scription factors plus B cell-related factors and others were not
changed in Aiolos−/− (our unpublished data). These moderate effects
of the Aiolos-deﬁciency on the gene expressions probably resulted in
insigniﬁcant changes in numbers of apoptotic cells (see Fig. 2).
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Fig. 2. Analyses of apoptosis in Aiolos−/−. (A) Effects of PMA/ionomycin and etoposide treatments on cell cycle distributions of DT40 and Aiolos−/−. DT40 and Aiolos−/− (clone 1)
cells treated with etoposide (10 μg/ml) for 6 h and PMA (10 ng/ml) plus ionomycin (1 μM) for 12 hwere processed for DNA content analysis by PI staining. Nuclei were analyzedwith
a Flow cytometry (FACSCalibur), and data for DT40 and Aiolos−/− were plotted on linear histograms as red ﬂuorescence intensity (x axis) against relative cell number (y axis).
Percentages of different cell cycle phases (sub-G1, G1, S and G2/M) of the two, together with those of two other Aiolos−/− (clones 2 and 3) are indicated in the table. (B) Sensitivity of
DT40 (squares) and Aiolos−/− (circles, triangles and lozenges) to PMA/ionomycin-mediated apoptosis. Cells were resuspended in DMEMmedium containing 10% (v/v) fetal bovine
serum and treated with (ﬁlled symbols) or without (open symbols) 10 ng/ml PMA plus 1 μM ionomycin at 37 °C up to 12 h. Viable cells were counted by the trypan blue dye exclusion
method. Data represent the average of two separate experiments. (C) Morphology of DT40 and Aiolos−/− (clone 1) treated with PMA/ionomycin. Cells were cultured for 24 h
without (No treatment) or with PMA/ionomycin (PMA/ionomycin), and their nucleus forms were analyzed by microscopy.
1307H. Kikuchi et al. / Biochimica et Biophysica Acta 1793 (2009) 1304–13143.2. Accelerated apoptotic induction by PMA/ionomycin in Aiolos−/−
We examined inﬂuences of PMA/ionomycin and etoposide on cell
cycle progressions and proliferations of DT40 and Aiolos−/−. The cells
cultured in the presence of PMA/ionomycin for 12 h or etoposide for
6 h were analyzed by FACS after staining with propidium iodide (PI)
(Fig. 2A). The treatment with etoposide, a topoisomerase-2 inhibitor,
caused apoptosis in the two cell lines at the same level. As described
[38], in DT40 the PMA/ionomycin treatments gave the cell cycle
distribution and apoptotic induction distinct from those with the
etoposide treatment. Interestingly, the PMA/ionomycin treatments
for Aiolos−/− instantly altered the cell cycle distribution with an
accelerated apoptotic cell death as compared to DT40. Further, we
examined effects of the PMA/ionomycin treatments on viability and
nuclear morphology of DT40 and Aiolos−/−. The viability of these twoFig. 1. Inﬂuence of Aiolos-deﬁciency on gene expressions of apoptosis-related factors. Total R
were determined by semiquantitative RT-PCR using appropriate primers. Chicken GAPDH
numbers. The gel images obtained were analyzed by Image Gauge software Proﬁle mode usin
in Aiolos−/− clones 1–3 are indicated as percentages of control values obtained from DT40cell lines remained unchanged in the absence of PMA/ionomycin, but
in the presence of the two drugs the viability of Aiolos−/− (∼20% at
12 h) was severely affected as compared to DT40 (∼70% at 12 h)
(Fig. 2B). Nucleus fragmentation, another characteristic of apoptosis,
was clearly heightened for Aiolos−/− than that for DT40 in the
presence of the two drugs (Fig. 2C). These results clearly revealed that
the Aiolos-deﬁciency in the DT40 cell line greatly compromises with
cell viabilitywith an accelerated apoptotic cell death in the presence of
PMA/ionomycin.
3.3. Moderate but distinct inﬂuences of PMA/ionomycin on gene
expressions of apoptosis-related factors in Aiolos−/−
To clarify the mechanism of apoptotic induction due to the Aiolos
lacking and BCR signaling, RT-PCR was carried out for various factorsNAwas extracted from DT40 and three independent Aiolos−/− clones, and mRNA levels
gene was used as an internal control. Numbers below the panels indicate PCR cycle
g a luminescent image analyzer LAS-1000plus. Data calibrated with the internal control
(wild type) in the table.
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Fig. 4. Effects of PKC inhibitors on the viability of DT40. DT40 cells were treated with
PKC inhibitor Go6976 (for cPKCs) or Rottlerin (for nPKCs) in the presence of PMA/
ionomycin for 12 h. Viable cells were counted by the trypan blue dye exclusion method.
Data represent the average of two separate experiments; error bars indicate standard
deviation.
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ments with these two drugs had almost similar effects onmRNA levels
of PKCι and PKCθ in DT40 and Aiolos−/−, while PKCα and PKCζmRNA
levels remained unchanged in Aiolos−/− but were decreased in DT40
(Fig. 3A). On the other hand, although mRNA levels of PKCβ, PKCδ,
PKCɛ and PKCη in Aiolos−/− were lower than those in DT40 (see Fig.
1), behaviors of PKCβ, PKCδ and PKCη mRNA levels against the PMA/
ionomycin treatments showed nearly same tendency, and interest-
ingly, the PKCɛmRNA level in Aiolos−/− reached to almost same level
of that in DT40 by 10 h (Fig. 3A). In DT40 and Aiolos−/− the PMA/
ionomycin treatments exhibited no impacts on transcript levels for
RelA, RelB, IKK-α plus IκB-β, and almost similar effects on those for
NFp52, IKK-β plus IκB-α. The mRNA level of c-Rel was increased to
∼150% in Aiolos−/− and to ∼230% in DT40 by 3 h, but thereafter
decreased to the control level and to ∼160% by 10 h (Fig. 3B and C).
Moreover, the transcript level of NFp50 was increased to ∼500% in
Aiolos−/− and to ∼850% in DT40 by 3 h, but thereafter decreased to
∼250% and to ∼500% by 10 h.
Aiolos-deﬁciency alone exhibited insigniﬁcant inﬂuences on gene
expressions of apoptosis-related factors bcl-2, bcl-xL, Apaf-1, cyto-
chrome c, PARP, AIF and AKT, except for that of bak (Figs. 1 and 3B).
PMA/ionomycin treatments showed no effect on the AKT gene
expression but slightly distinct effects on expressions of remaining
apoptosis-related genes (Fig. 3C). In DT40 and Aiolos−/− the mRNA
level of bcl-xL was decreased to ∼40% by 3 h but thereafter remained
unchanged up to 10 h. The transcript levels of bcl-2, PARP and AIFwere
decreased to ∼70% by 3 h, and thereafter signiﬁcantly to ∼40%, ∼50%
and ∼60%, respectively, by 10 h in Aiolos−/−, whereas they were
insigniﬁcantly decreased to ∼80%, ∼90% and ∼90% by 3 h followed by
the increase to control levels in DT40. In DT40 and Aiolos−/− the
mRNA level of Apaf-1 was decreased to ∼80% by 3 h and thereafter
increased to the control level by 10 h. Interestingly, the mRNA level of
bak, whichwas increased to∼200% due to the Aiolos-deﬁciency alone,
was decreased to almost control level by 3 h, and further decreased to
∼50% by 10 h, although in DT40 bak mRNA level remained unchanged
by 10 h. Moreover, in Aiolos−/− the mRNA level of cytochrome c was
unchanged by 3 h but thereafter slightly decreased to ∼80% by 10 h,
whereas in DT40 the mRNA level remained unchanged over 10 h.
Depletion of Aiolos alone certainly decreased the ICAD mRNA
level (to ∼60%), but possessed no effect on the gene expression of
CAD (Fig. 3B), in agreement with ﬁndings in Fig. 1. The PMA/
ionomycin treatments showed almost similar effect on the gene
expression of CAD in DT40 and Aiolos−/−, i.e. the CAD mRNA level
was slightly decreased (to ∼65%) by 3 h but thereafter increased to a
control level by 10 h. Conversely, the two drugs–treatments slightly
exhibited distinct effect on the gene expression of ICAD in DT40 and
Aiolos−/−. The ICAD mRNA level in Aiolos−/− was decreased (from
∼60% to ∼30%) by 3 h and remained unchanged by 10 h, whereas
the mRNA level in DT40 was rapidly decreased (from 100% to ∼40%)
by 3 h and also remained unchanged (at the same level of the
mutant) by 10 h.
Aiolos-depletion alone exhibited no effects on expressions of
caspase-3, caspase-6, caspase-8 and caspase-10 genes, except for that
of caspase-9 gene (Fig. 3B), consistent with those in Fig. 1. In DT40 and
Aiolos−/− caspase-3 mRNA level remained unchanged even in the
presence of PMA and ionomycin by 10 h (Fig. 3B). In the two cell lines
the mRNA level of caspase-8 was increased to ∼190% by 3 h and
remained unchanged by 10 h (Fig. 3C). Interestingly, the increasedFig. 3. Effects of PMA/ionomycin treatments on gene expressions of PKCs, NF-κBs, NF-κB-regu
Typical RT-PCR patterns of PKCs in PMA/ionomycin-treated DT40 and Aiolos−/−. Total RNA
times up to 10 h, and mRNA levels of appropriate genes were determined by RT-PCR. Data ana
as percentages of control values obtained from DT40 (0 h). (B) Typical RT-PCR patterns o
appropriate genes were determined by RT-PCR as in (A). Chicken GAPDH genewas used as a
Total RNAwas extracted from two other PMA/ionomycin-treated Aiolos−/− (clones 2 and 3)
RT-PCR. Data for DT40 (circles) and three Aiolos−/− (clones 1–3) (squares, triangles and lomRNA level (∼150% of the control level) of caspase-9 in Aiolos−/−
remained unchanged by 3 h but thereafter slightly decreased to
∼120% by 10 h, although the mRNA level in DT40 was unchanged by
3 h but thereafter increased to almost same level in Aiolos−/−.
Depletion of Aiolos alone exhibited insigniﬁcant effects on
expressions of caspase-regulating factors FLIP, IAP1, IAP2, survivin
and Smac genes (Fig. 3B), consistent with those depicted in Fig. 1. In
the presence of PMA and ionomycin, IAP1 mRNA level was slightly
increased by 3 h without any subsequent change by 10 h in DT40 and
Aiolos−/−. FLIP mRNA level was slightly decreased (to ∼80%) by 3 h
but thereafter increased (to ∼140% and to the control level,
respectively) by 10 h in DT40 and Aiolos−/−. Survivin and Smac
mRNA levels were slightly decreased (to ∼70% and to ∼80%) by 3 h
with subsequent increase to control levels by 10 h in DT40 and
Aiolos−/−. In DT40 and Aiolos−/− IAP2 mRNA level was signiﬁcantly
decreased (to ∼35%) by 3 h without any further alteration by 10 h.
3.4. Signal transduction for cell survival via nPKC/NF-κB pathway
Go6976 or Rottlerin is known to inhibit preferentially cPKCs (PKCα,
PKCβ, PKCγ) or nPKCs (PKCδ, PKCɛ, PKCθ, etc.) plus aPKCs (PKCζ, etc.).
To know the BCR signaling pathway in the pre-mature B cell line, we
treated DT40 with each of these two inhibitors in the presence of
PMA/ionomycin for 12 h. Viability of DT40 was signiﬁcantly reduced
by Rottlerin as compared to Go6976 (Fig. 4), since each inhibitor
(1 μM) showed insigniﬁcant effect on cell viability in the absence of
PMA/ionomycin (data not shown). These ﬁndings indicated that the
BCR signaling, which is mimicked by PMA/ionomycin, is mainly
transduced through nPKCs (PKCδ and PKCθ), and/or aPKCs, but not by
cPKCs, consistent with results with GCN5−/− [38].
3.5. PMA/ionomycin-mediated apoptosis of Aiolos−/− is accelerated by
elevated cytochrome c release from mitochondria, increased
caspase-9/caspase-3 activities and reduced amounts of ICAD
Our results so far suggested that apoptosis of Aiolos−/− is
rapidly induced by the PMA/ionomycin treatments (compared withlating factors, apoptosis-related factors, CAD/ICAD, caspases and caspase inhibitors. (A)
was extracted from PMA/ionomycin-treated DT40 and Aiolos−/− (clone 1) at indicated
lyzed using a luminescent image analyzer LAS-1000plus are indicated under the panels
f various genes in PMA/ionomycin-treated DT40 and Aiolos−/−. The mRNA levels of
control. (C) Time-courses of various gene expressions after PMA/ionomycin treatments.
at indicated times up to 10 h, and mRNA levels of appropriate genes were determined by
zenges) were analyzed using a luminescent image analyzer LAS-1000plus.
Fig. 5. Cytochrome c releasing assay. DT40 and three Aiolos−/− (clones 1–3) were treated with PMA/ionomycin for 4 h. Cells were fractionated into cytosol and mitochondria
fractions and each fraction (10 μg/lane) was analyzed by immunoblotting with anti-cytochrome c or anti-Bcl-2 antibody.
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mechanism of the drugs-mediated apoptosis of Aiolos−/− should be
somewhat distinct from those of E2A−/− and DT40. Interestingly,
the expression of bak gene was remarkably increased in Aiolos−/−
(Figs. 1 and 3). Therefore, we examined the inﬂuence of PMA/
ionomycin on cytochrome c release from mitochondria to cytosol in
DT40 and Aiolos−/−. To conﬁrm purity of mitochondria and
cytosolic fractions, we measured the amount of the mitochondrial
marker protein Bcl-2. The protein level of Bcl-2 was detectable in
the mitochondria fraction but not in the cytosolic fraction in both
cases of the treatment and non-treatment with PMA/ionomycin,
indicating that the subcellular fractionation was thorough. We
measured the amounts of cytochrome c in mitochondria and cytosol
fractions by immunoblotting (Fig. 5). As expected, in the absence of
the two drugs (Resting) almost all of cytochrome c was localized in
the former fraction but not in the latter fraction in Aiolos−/− and
DT40. Noticeably, PMA/ionomycin treatments obviously altered the
amounts of cytochrome c in mitochondria or cytosol fractions of
Aiolos−/−, compared with those of DT40. These results indicated
that the two drugs–treatments, which mimic the BCR stimulation,
directly and/or indirectly accelerate cytochrome c release from
mitochondria to cytosol in Aiolos−/−.
Next, we examined inﬂuences of the PMA/ionomycin treatments on
caspase activities (Fig. 6A). As expected, caspase-9 activity was slightly
higher in Aiolos−/− than in DT40, possibly due to its higher mRNA level
even in the absence of PMA/ionomycin in themutants (see Figs.1 and 3).
Interestingly, in Aiolos−/− the treatments showed clearly elevated
activities of caspase-3 (to ∼400% by 4 h and ∼200% by 8 h), caspase-8
(to ∼150% by 4 h and ∼170% by 8 h) and caspase-9 (to ∼180% by 4 h and
∼170% by 8 h), compared with DT40. In addition, we examined the
inﬂuences of the two drugs on conversion of pro-caspase-3 (36K) to its
active forms (20 K and 15 K) by immunoblotting. As shown in Fig. 6B, the
treatments showedobviously increased amounts of activated caspase-3 in
Aiolos−/−. These ﬁndings indicated that the PMA/ionomycin treatments
elevate these three caspase activities more rapidly in Aiolos−/− than in
DT40 through conversion of pro-caspase-3 to activated caspase-3.Fig. 6. Analyses of mechanisms of the sensitivity of Aiolos−/− against PMA/ionomycin-me
lysates were prepared from PMA/ionomycin-treated DT40 (circles) and Aiolos−/− (clones 1
assays were performed using appropriate caspase assay kits. Absorbance at 405 nm was m
experiments; error bars indicate standard deviation. (B) Effects of PMA/ionomycin treatmen
from PMA/ionomycin-treated DT40 and Aiolos−/− at 4 h and subjected to SDS-PAGE fo
conjugated with horse radish peroxidase, and data were analyzed using a luminescent image
are indicated. (C) Effects of PMA/ionomycin treatments on protein levels of ICAD. Whole prot
up to 10 h and subjected to SDS-PAGE followed by immunoblotting. Antibody binding was det
actinwas used as a control. Apparentmolecular weights of marker proteins are indicated. Rig
and three Aiolos−/− (clones 1–3). Datawere expressed as percentages of control (DT40 at 0 h
DNA was isolated from DT40 and Aiolos−/− incubated with PMA/ionomycin for 0, 3, 6 and 1
HindIII are indicated in base pairs. Left panel: Typical electrophoregram of DNA extracted from
DNA extracted from PMA/ionomycin-treated DT40 and three Aiolos−/− (clones 1–3) at 6 h.Further, we examined the effects of the PMA/ionomycin
treatments at the cellular level of ICAD, a proximal factor to control
the CAD activity for DNA fragmentation, by immunoblotting (Fig.
6C). Aiolos-deﬁciency alone decreased the ICAD protein level (to
∼40%), probably due to its lower mRNA level (Figs. 1 and 3). In
DT40 the PMA/ionomycin treatments exhibited no effect on the
ICAD protein level by 3 h but decreased to ∼50% by 10 h, consistent
with results in the previous report [38]. Remarkably, in Aiolos−/−
the PMA/ionomycin treatments quickly diminished the ICAD protein
level, which was already decreased to ∼40% by the Aiolos lacking
alone as mentioned above, to ∼25% by 3 h and to less than
detectable level by 6 h. This acute suppression of the ICAD protein
level at early stage of exposure to PMA/ionomycin in Aiolos−/−
could be possibly due to its huge degradation by elevated caspase-3
activity, although the ICAD mRNA level was decreased by 3 h but
thereafter remained unchanged, as in DT40 (Fig. 3).
Alterations in the CAD transcript level were similar in DT40 and
Aiolos−/− (Fig. 3B). Its protein level could not be detected by available
antibodies. To knowthe CAD activity,weﬁnally examined the effects of
the PMA/ionomycin treatments on DNA fragmentation (Fig. 6D). The
DNA fragmentation for Aiolos−/− was more prominent, compared
with moderate level for DT40 (Fig. 6D, left panel). Such DNA
fragmentation patterns were reproducible in two other Aiolos−/−
clones (Fig. 6D, right panel). These results indicated that in Aiolos−/−
treated with PMA/ionomycin the enhanced CAD activity should be
the consequence of the dramatically reduced amount of its
inhibitor ICAD, resulting in heightened DNA fragmentation.
3.6. Re-expression of Aiolos isoform Aio-2 recovers the susceptibility of
Aiolos−/− to PMA/ionomycin-mediated apoptosis
To conﬁrm the role of Aiolos in PMA/ionomycin-mediated apoptosis,
re-expression study was carried out using Aiolos (Aio-1 and Aio-2)
expression vectors. The resulting transfectant clones Aiolos−/−/Aio-1
and Aiolos−/−/Aio-2, respectively, which express largely Aio-1 and Aio-
2 genes (to∼500%and to∼400%) comparedwith thoseofAiolos inDT40diated apoptosis. (A) Effects of PMA/ionomycin treatments on caspase activities. Cell
–3) (squares, triangles and lozenges) at indicated times up to 8 h and caspase activity
easured to determine caspase activities. Data represent the average of two separate
ts on conversion of pro-caspase-3 to activated caspase-3. Whole proteins were isolated
llowed by immunoblotting. Antibody binding was detected using second antibodies
analyzer. β-actin was used as a control. Apparent molecular weights of marker proteins
eins were isolated from PMA/ionomycin-treated DT40 and Aiolos−/− at indicated times
ected as in (B). Left panel: Typical immunoblot pattern (DT40 and Aiolos−/− clone 1). β-
ht panel: Time-course of protein levels of ICAD after PMA/ionomycin treatments in DT40
). (D) Effects of PMA/ionomycin treatments on DNA fragmentation inDT40andAiolos−/−.
0 h and analyzed by 1.5% agarose gel electrophoresis. The sizes of λ-DNA digested with
PMA/ionomycin-treated DT40 and Aiolos−/− (clone 1). Right panel: Electrophoregram of
1311H. Kikuchi et al. / Biochimica et Biophysica Acta 1793 (2009) 1304–1314(Fig. 7, left panel) and synthesize deﬁnite amounts of FLAG-tagged Aio-1
and Aio-2 proteins (Fig. 7A, right panel), were used to study the
complementation of the accelerated susceptibility to PMA/ionomycin-
mediated apoptosis. First, we examined the effects of the PMA/
ionomycin treatments on viability and DNA fragmentation of DT40,
Aiolos−/−, Aiolos−/−/Aio-1 and Aiolos−/−/Aio-2. Interestingly, the
viability of Aiolos−/− dramatically recovered up to the same level ofthat in DT40 by re-expression of Aio-2, while the viability of Aiolos−/−
did not recover by re-expression of Aio-1 (Fig. 7B, left panel). Moreover,
DNA fragmentation of Aiolos−/− was rather accelerated by re-expres-
sion of Aio-1, whereas it was thoroughly protected by re-expression of
Aio-2 (Fig. 7B, right panel). These results suggested that Aio-2 (not Aio-
1) was able to restore the susceptibility of Aiolos−/− to PMA/
ionomycin-mediated apoptosis. Next, to know the effects of re-
1312 H. Kikuchi et al. / Biochimica et Biophysica Acta 1793 (2009) 1304–1314expressions of Aiolos (Aio-1 and Aio-2) on transcription of the genes
altered in Aiolos−/− (see Fig. 1), we carried out RT-PCR on total
mRNAs prepared from DT40, Aiolos−/−, two independent Aiolos−/−/
Aio-1 clones and two independent Aiolos−/−/Aio-2 clones (Fig. 7C).
Re-expressions of Aio-1 and Aio-2 had only a slight effect on mRNA
levels of PKCα, PKCβ and ICAD. PKCɛ, PKCζ and caspase-9 mRNA
levels were recovered to almost similar levels of DT40 by re-
expressions of Aio-1 and Aio-2. PKCδ mRNA level was increased to
∼130% of control (DT40) by re-expression of Aio-2, while PKCη mRNA
level was recovered to ∼60% of control (DT40) by re-expression of
Aio-1. Interestingly, transcription of the bak gene, an apoptosis-
promoting gene belonging to bcl-2 family, was remarkably down-
regulated by re-expression of Aio-2 (∼25%), whereas it was notably
up-regulated by re-expression of Aio-1 (∼300%).
4. Discussion
Recently, by analyzing the GCN5-deﬁcient DT40 cell line, GCN5−/−,
we showed that GCN5 and BCR stimulation mimicked by the PMA/
ionomycin treatments are linked with apoptosis of the pre-mature B
cell line [38]. In fact, GCN5 and BCR signaling together enforce the
apoptosis via nuclear DNA fragmentation by enhancing CAD activity
due to depletions of ICAD/IAP2 and elevations of caspase-8/caspase-3
activities [38]. We also revealed that the E2A-deﬁciency prevents
apoptosis of DT40 through BCR signaling pathway [41]. On the other
hand, it was also reported that the Aiolos disruption in the DT40 cell
line induces a cell death sensitive phenotype, i.e. Aiolos−/− cells are
more prone to apoptosis under nutritional stress, BCR cross-linking
and UV- or γ-irradiation [36]. Even though Aiolos is critically involved
in the normal lymphoid system development, its role in inducing
apoptosis remains to be completely resolved.
Here we have studied the participation of Aiolos in the apoptotic
induction of DT40 cell line by exposing Aiolos−/− to PMA/ionomycin.
In agreement with the ﬁndings reported previously [36], Aiolos-
deﬁciency certainly accelerated apoptosis of DT40 cells via BCR
signaling (Fig. 2). The inﬂuences of the Aiolos-deﬁciency are opposite
to those of the E2A lacking, with regard to twomajor characteristics of
B lymphocytes, i.e. IgM H/L-chain production [32] and BCR signaling-
mediated apoptosis [41]. Additionally, the apoptotic cell death of
Aiolos−/− is induced at early stage of the PMA/ionomycin exposure
(Fig. 2B).
Aiolos-deﬁciency alone had minor inﬂuence on mRNA levels of
bak, caspase-9 and ICAD, i.e. the elevation (∼200%) for the former two
and the slight suppression for the last (Figs. 1 and 3). These altered
amounts of caspase-9 and ICAD transcripts should be the cause for not
only that the ICAD protein level was lower (∼40%) in Aiolos−/− than
in DT40, but also that the caspase-9 activity was relatively higher in
Aiolos−/− than in DT40 (Fig. 6). Interestingly, during the early stage
of PMA/ionomycin exposure (by 3 h), the mRNA level of bak in
Aiolos−/− was decreased but relatively higher than that in DT40 (Fig.
3). The PMA/ionomycin treatments had no effects on the transcrip-
tions of cytochrome c and caspase-9 in Aiolos−/− and DT40 by 3 h,
whereas the mRNA levels of the former and the latter in Aiolos−/−
were decreased to ∼75% and to the control level by 10 h (Fig. 3). On
the other hand, the ICADmRNA level was relatively lower in Aiolos−/−
than in DT40 in the absence of the two drugs, but decreased to same
level in Aiolos−/− and DT40 by 3 h and thereafter remained
unchanged by 10 h.
Interestingly, the amount of ICAD was dramatically diminished in
Aiolos−/− but remained unchanged in DT40 during the early stage of
the PMA/ionomycin treatments (by 3 h), and decreased to
undetectable level in Aiolos−/− or to ∼75% in DT40 by 6 h (Fig.
6C). Moreover, during the early stage of the treatments (by 4 h),
caspase-3, caspase-8 and caspase-9 activities were elevated in
Aiolos−/−, without any alterations in DT40 (Fig. 6A). The heightened
activities of these three caspases at the early stage of the PMA/ionomycin treatments in Aiolos−/−, even though the treatments
exhibited insigniﬁcant inﬂuences on the transcript (and also probably
protein) levels of these three, could be explained as follows. In the
absence of PMA/ionomycin almost all of cytochrome c was localized
in the mitochondria but not in cytosol fractions in Aiolos−/− and
DT40, whereas in Aiolos−/− the two drugs–treatments obviously
decreased or increased the amount of cytochrome c in the
mitochondria or cytosol fraction, with a comparatively lesser extent
of such alterations in DT40 (Fig. 5). Therefore, the PMA/ionomycin
treatments, which mimic the BCR signaling, immediately induce
directly and/or indirectly the cytochrome c release from mitochon-
dria to cytosol in the absence of Aiolos.
Gene expressions of PKCδ, PKCɛ and PKCζ, respectively, which
should be involved in cell survival through BCR signaling
[24,26,27,42], are usually expressed at sufﬁcient levels for normal
signal transduction by BCR stimulation in the DT40 cell line. The
Aiolos-deﬁciency dramatically decreased the mRNA levels of PKCα,
PKCβ, PKCδ, PKCɛ, PKCη and PKCζ, without any effects on PKCι, PKCμ
and PKCθ transcripts (Figs. 1 and 3A). Further, the Rottlerin treatment,
which is known to inhibit nPKCs (especially PKCδ), accelerated the
PMA/ionomycin-induced apoptosis of DT40 (Fig. 4). These ﬁndings
suggested that the decreased mRNA levels of these PKCs may lead to
the immediate induction of apoptosis of Aiolos−/− in the presence of
PMA/ionomycin via the down-regulation of the survival signals. Thus,
the increased cytochrome c release from mitochondria and sup-
pressed gene expressions of nPKCs independently or synergistically
should cause the heightened sensitivity of Aiolos−/− to the PMA/
ionomycin-induced apoptosis.
Re-expression study showed that Aio-2 alone is sufﬁcient to
completely restore the susceptibility of Aiolos−/− to PMA/ionomycin-
mediated apoptosis (Fig. 7). By analyzing Aiolos−/−/Aio-1 and
Aiolos−/−/Aio-2, we revealed that Aio-1 and Aio-2 each up-regulate
expressions of PKCɛ and PKCζ genes, and down-regulate the
expression of caspase-9 gene. However, re-expression of each of
Aio-1 and Aio-2 slightly recovers expressions of PKCα, PKCβ and ICAD
genes. Both Aio-1 and Aio-2 may be required to perfectly recover their
expressions. In addition, the gene expression of PKCδ or PKCη is up-
regulated by re-expression of Aio-2 or Aio-1. As mentioned above,
PKCδ is a major target enzyme of Rottlerin. Results obtained by
Rottlerin treatment and re-expression of Aio-2 revealed that PKCδ is
one of the key enzymes involved in PMA/ionomycin-mediated
apoptosis in DT40. Further, the expression of the bak gene is
remarkably down-regulated or up-regulated by re-expression of
Aio-2 or Aio-1, respectively. As is well known, the product of the
bak gene belonging to the bcl-2 family is one of the key molecules in
the mitochondrial pathway of apoptosis, leading to cytochrome c
release from mitochondria. Therefore, Aio-2 must control PMA/
ionomycin-mediated apoptosis via regulating the expressions of
PKCδ and bak genes. However, Aiolos−/− would never return to wild
type by re-expression of Aio-2 alone. These results suggest that the
balanced expression of both Aio-1 and Aio-2 isoforms would be
required for regulation of apoptosis induced by the PMA/ionomycin
treatments, which mimic the BCR stimulation, in pre-mature B cell
(DT40).
In summary, the Aiolos-deﬁciency accelerates apoptosis of pre-
mature B cells via BCR signaling pathway. Both of the Aiolos-
deﬁciency and BCR signaling immediately and cooperatively control
this pre-mature B cell apoptosis via dramatically elevated cytochrome
c release from mitochondria to cytosol, which is possibly accom-
panied with the increased protein level of bak and the suppressed
expressions of nPKCs. This particular alteration results in elevated
caspase-9 and caspase-3 (and also caspase-8) activities, and
drastically diminished amounts of ICAD, followed by increased
DNA fragmentation (Fig. 6D). These ﬁndings should become a
powerful trigger to help remarkably in the understanding of
autoimmune diseases and B cell lymphomas, through resolving
Fig. 7. Re-expression study of Aiolos. Expression vector carrying each of isoforms Aio-1 and Aio-2 genes was transfected into Aiolos−/− cells. The resulting transfectant clones
(Aiolos−/−/Aio-1 and Aiolos−/−/Aio-2) were cultured and used for various studies. (A) Re-expressions of isoforms Aio-1 and Aio-2. Left panel: RT-PCR. Total RNA was extracted
from DT40, Aiolos−/−, two independent Aiolos−/−/Aio-1 and two independent Aiolos−/−/Aio-2 and RT-PCR using Aiolos primers [38] was carried out. Chicken GAPDH gene
was used as a control. Right panel: Immunoblotting. Whole proteins were isolated from Aiolos−/−, Aiolos−/−/Aio-1 and Aiolos−/−/Aio-2, and subjected to SDS-PAGE followed
by immunoblotting using anti-FLAG antibody as a primary antibody. (B) Sensitivity of Aiolos−/−/Aio-1 and Aiolos−/−/Aio-2 to PMA/ionomycin-mediated apoptosis. Left panel:
Viability. DT40 (circles), Aiolos−/− (squares), Aiolos−/−/Aio-1 (triangles), Aiolos−/−/Aio-2 (lozenges) cells were resuspended in DMEM medium containing 10% (v/v) fetal
bovine serum and treated with 10 ng/ml PMA plus 1 μM ionomycin at 37 °C up to 12 h. Viable cells were counted by the trypan blue dye exclusion method. Data represent the
average of two separate experiments. Right panel: DNA fragmentation analysis. DNAwas extracted from PMA/ionomycin-treated DT40, Aiolos−/−, two independent Aiolos−/−/Aio-1
clones and two independent Aiolos−/−/Aio-2 clones at 6 h and analyzed by 1.5% agarose gel electrophoresis. The sizes of λ-DNA digested with HindIII are indicated in base pairs. (C)
Inﬂuences of re-expressions of two Aiolos isoforms on gene expressions of PKCs, ICAD, bak and caspase-9. Total RNA was extracted from DT40, Aiolos−/−, two independent
Aiolos−/−/Aio-1 clones and two independent Aiolos−/−/Aio-2 clones. mRNA levels were determined by semiquantitative RT-PCR using appropriate primers. Data were analyzed
using a luminescent image analyzer LAS-1000plus and indicated as percentages of control values obtained from DT40. Data represent the average of two separate experiments;
error bars indicate standard deviation.
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